ATW SPAC Management’s Orchestra BioMed OBIO Stock Holding History

ATW SPAC Management’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-191,659	Closed	-$1.91M	–	313
2022 Q2	$1.91M	Hold	191,659	–	–	0.27%	116
2022 Q1	$1.9K	Buy	191,659 +34,500	+22%	+$341K	0.26%	113
2021 Q4	$1.58M	Hold	157,159	–	–	0.24%	115
2021 Q3	$1.55M	Hold	157,159	–	–	0.29%	82
2021 Q2	$1.6M	Buy	+157,159	New	+$1.63M	0.41%	68

Other funds holding OBIO

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

ATW SPAC Management's OBIO Position: Q3 2022 in Review

ATW SPAC Management sold out of Orchestra BioMed (OBIO) in Q3 2022, closing a stake of 191,659 shares — an estimated $1.91M sold.

ATW SPAC Management first reported a position in OBIO in Q2 2021 and held it in 5 quarters. The position peaked at $1.91M in Q2 2022. 23 funds tracked by Wall St. Rank hold OBIO as of Q3 2022.

ATW SPAC Management reported no remaining Orchestra BioMed position as of Q3 2022 after selling out during the quarter.
ATW SPAC Management sold 191,659 Orchestra BioMed shares in Q3 2022, an estimated $1.91M.
ATW SPAC Management first reported a position in Orchestra BioMed in Q2 2021 and held it in 5 quarters.
ATW SPAC Management's Orchestra BioMed position peaked at $1.91M in Q2 2022.
23 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2022.

Based on ATW SPAC Management's 13F filing for Q3 2022, filed 14 Nov 2022.